Thanks to a better fundamental star rating, CANSINO BIOLOGICS sees an ...

The independent financial analyst theScreener just awarded an improved star rating to CANSINO BIOLOGICS (CN), active in the Pharmaceuticals industry. As regards its fundamental valuation, the title receives an improved star rating and now shows 3 out of 4 possible stars. With regard to its market behaviour, it remains unchanged and can be qualified as risky. theScreener considers that these elements allow slightly upgrading its rating to Neutral. As of the analysis date December 31, 2021, the cl...